Form 8-K Anthera Pharmaceuticals For: Nov 14

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. RXO
8. GOOGL
9. GMAB
10. USO

Go back to Form 8-K Anthera Pharmaceuticals For: Nov 14

Anthera Pharma (ANTH) Reports Q3 Loss of 31c/Share

November 17, 2014 9:45 AM EST

Anthera Pharma (NASDAQ: ANTH) reported Q3 EPS of ($0.31), versus ($0.30) reported last year.

Third Quarter Operational Update:

Blisibimod

Our Phase 3 systemic lupus erythematosus clinical study, CHABLIS-SC1, is recruiting patients in Eastern Europe, Latin America and Southeast Asia. To date, we have enrolled over 260 of the 400 patients planned for the CHABLIS-SC1 study. Enrolled patient demographics and disease characteristics for the CHABLIS-SC1 study continued to be consistent with our goal to enroll patients with higher levels of lupus activity and positive biomarkers despite the stable use of corticosteroids.... More